What is Zacks Research’s Forecast for Sanofi Q1 Earnings?

Sanofi (NASDAQ:SNY) – Zacks Research reduced their Q1 2026 earnings estimates for shares of Sanofi in a research note issued on Wednesday, February 19th. Zacks Research analyst K. Shah now anticipates that the company will earn $1.05 per share for the quarter, down from their prior forecast of $1.06. The consensus estimate for Sanofi’s current full-year earnings is $4.36 per share. Zacks Research also issued estimates for Sanofi’s Q4 2026 earnings at $1.19 EPS, FY2026 earnings at $4.75 EPS and FY2027 earnings at $5.16 EPS.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%.

A number of other analysts also recently issued reports on SNY. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $60.00.

Sanofi Stock Up 1.0 %

SNY opened at $54.13 on Friday. The firm has a 50 day moving average price of $50.79 and a 200 day moving average price of $52.50. The company has a market cap of $137.37 billion, a PE ratio of 21.74, a price-to-earnings-growth ratio of 1.00 and a beta of 0.57. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46.

Hedge Funds Weigh In On Sanofi

A number of institutional investors and hedge funds have recently bought and sold shares of SNY. Synergy Asset Management LLC purchased a new position in Sanofi in the 4th quarter worth approximately $25,000. McClarren Financial Advisors Inc. boosted its holdings in Sanofi by 952.6% in the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after acquiring an additional 543 shares during the period. Lee Danner & Bass Inc. purchased a new position in shares of Sanofi during the 4th quarter valued at approximately $31,000. Bessemer Group Inc. boosted its stake in shares of Sanofi by 59.8% during the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company’s stock valued at $32,000 after buying an additional 242 shares during the last quarter. Finally, Concord Wealth Partners boosted its stake in shares of Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after buying an additional 363 shares during the last quarter. Hedge funds and other institutional investors own 14.04% of the company’s stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.